This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Kang, C.-I.
Right arrow Articles by Patel, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, C.-I.
Right arrow Articles by Patel, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2009, p. 3576-3578, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00646-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Anidulafungin Treatment of Candidal Central Nervous System Infection in a Murine Model {triangledown}

Cheol-In Kang,1,2 Mark S. Rouse,2 Jayawant N. Mandrekar,3 James M. Steckelberg,2 and Robin Patel2,4*

Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea,1 Division of Infectious Diseases, Department of Medicine,2 Division of Biostatistics and Informatics, Department of Health Sciences Research,3 Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, Minnesota4

Received 12 May 2009/ Returned for modification 16 May 2009/ Accepted 29 May 2009

We established a murine model of Candida albicans central nervous system (CNS) infection and evaluated the efficacy of anidulafungin. Ten milligrams/kg/day anidulafungin, amphotericin B, or voriconazole significantly reduced mortality and fungal burden in brain tissue, although amphotericin B and 10 mg/kg/day anidulafungin reduced fungal burden in brain tissue to a greater extent than did voriconazole. This suggests a potential role for anidulafungin in the treatment of candidal CNS infection.

* Corresponding author: Division of Clinical Microbiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: (507) 538-0579. Fax: (507) 284-4272. E-mail: patel.robin{at}mayo.edu

{triangledown} Published ahead of print on 8 June 2009.

Antimicrobial Agents and Chemotherapy, August 2009, p. 3576-3578, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00646-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»